We believe that the acquisition will materialize as we are confident that the breast cancer product, Trodelvy, is important for Gilead’s oncology section. Especially since it has been approved for the difficult to treat triple-negative breast cancer; before Immunomedics’ drug Trodelvy no official treatment had been approved
AstraZeneca Halted Trial Resumed
AstraZeneca (AZN) had paused the trial of its COVID-19 vaccine, developed with Oxford University. The pause was decided upon to enable an independent committee to investigate a single event of an unexplained illness that occurred in the UK on one of the recruited volunteers who were vaccinated by AsrtraZeneca’s AZD1222 vaccine in the Phase 3 trial.
On September 12, 2020 the clinical trials for the AstraZeneca Oxford coronavirus vaccine AZD1222 resumed.
The decision was made following confirmation from both the Medicines Health Regulatory Authority (MHRA) and the UK committee investigations that it was safe to resume the trial in the UK.
AstraZeneca and the University of Oxford, as the trial sponsor, cannot disclose further medical information. All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.
AstraZeneca will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic.
Some analysts expressed their belief that AstraZeneca is destined to be the first to deliver the COVID-19 vaccine.
AstraZeneca announced its readiness to manufacture the vaccine in the fall if the drug is approved.
This is good news.
To read more about these firms and COVID-19 please use the search engine at our website.
Gilead Sciences Could Acquire Immunomedics at $20 Billion. See Also: AstraZeneca Vaccine Trial Resumed
Gilead Sciences News Is Not Just Gossip
Real news, not just gossip, is spreading today about Gilead Sciences (GILD) nearing a deal to acquire the biotech firm Immunomedics (IMMU) for $20 billion. Immunomedics current market value is around $10 billion which means that Gilead is buying it at double its value.
The deal could be announced on Monday, if not sooner, if the talks go smoothly and do not stall for one reason or another.
Immunomedics sells its breast cancer anti-body drug candidate, Trodelvy, which was granted approval in April for the treatment of triple-negative breast cancer. That could be the reason behind Gilead’s attraction as the firm is already working on growing its oncology portfolio which started with the acquisition of Kite Pharmaceuticals and recently succeeded in stretching its CAR T market by increasing the number of cancers treated with its immuno-oncology CAR T product.
Please read the recent articles we posted about Gilead by clicking here.